The study found that nerandomilast effectively slowed lung function decline in patients, with discontinuation rates similar to placebo
Adverse events were consistent with valbenazine’s established safety profile
The therapy also drove additional weight loss at the higher 1.8 mg dose without plateauing and maintained a favorable tolerability profile
FOP is a rare genetic disorder caused by mutations in the ALK2 kinase
Takeda said zasocitinib was generally well tolerated, with a safety profile consistent with earlier studies
The approval for Exdensur (depemokimab-ulaa) comes on the back of SWIFT-1 and SWIFT-2 Phase III trials
At one year, the drug met its primary and all key secondary endpoints, delivering significantly better weight maintenance than placebo
The trial met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival
If cleared by regulators, CagriSema would become the first treatment to combine a GLP-1 receptor agonist and a long-acting amylin analogue in a single injection
The upcoming trials will evaluate both active and chronic TED in randomized, double-blind, placebo-controlled studies
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
